A patient found to carry a BRCA1 pathogenic variant is not referred to a certified genetic counselor in her health system.

AlleyWatch sat down with Nucleus CEO and Founder Kian Sadeghi to learn more about the business, its future plans, and recent ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...

DNA transcription is the vital first step needed for switching on our genes. For a gene to be switched on, it must be acted ...

We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...

Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics, Inc. is headquartered in Salt Lake City, UT. The company is focused on developing, producing and distributing genetic tests utilized in the oncology and women's and ...

EU-backed researchers and doctors are pioneering advanced pre-implantation and prenatal genetic ... the lab into real-life solutions. The team aims to improve PGT, non-invasive prenatal testing ...

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary ... planned electronic medical record integration of Myriad's tests for ...

The NCCN's new resource educates patients on genetic testing for hereditary cancer risk, focusing on breast, ovarian, pancreatic, and prostate cancers. Advances in genetic technology, spurred by ...